In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until condition progression or even the individuals are unable to tolerate the study drugs. Attainable new approaches to the analysis and treatment of AML. (A) The identification https://theodorf444teo7.ourabilitywiki.com/user